2011
PD05-04: Quantitative Measurement of Antigen Degradation in NCCTG N9831 Tissue Microarrays.
Cheng H, Rimm D, Reinholz M, Lingle W, Ballman K, Dueck A, Chen B, McCullough A, Jenkins R, Perez E. PD05-04: Quantitative Measurement of Antigen Degradation in NCCTG N9831 Tissue Microarrays. Cancer Research 2011, 71: pd05-04-pd05-04. DOI: 10.1158/0008-5472.sabcs11-pd05-04.Peer-Reviewed Original ResearchCooperative group studiesTissue microarrayAntigen degradationAdjuvant phase III trialsPhase III trialsGroup studyExpression of HER2Paraffin-embedded tissuesIII trialsEntire cohortExpression of HER1Analysis of biomarkersPositive casesHER2Quantitative immunofluorescenceTumor samplesCancer ResHER2 scoreTissue blocksOld casesTissue collectionAverage scoreHER1TMA slidesPre-analytical variables
2005
Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis
McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis. Journal Of The National Cancer Institute 2005, 97: 1808-1815. PMID: 16368942, DOI: 10.1093/jnci/dji427.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, NeoplasmBiomarkers, TumorCell Line, TumorConfidence IntervalsEnzyme-Linked Immunosorbent AssayFemaleFluorescent Antibody TechniqueGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMiddle AgedNeoplasmsOdds RatioPredictive Value of TestsPrognosisProtein Array AnalysisReceptor, ErbB-2Receptors, EstrogenSurvival AnalysisTreatment OutcomeTumor Suppressor Protein p53ConceptsDisease-specific mortalityHigh HER2 expressionHER2 expressionAntibody concentrationsHigh expressionPoor survivalRelative riskTissue microarrayCumulative disease-specific survivalBiomarker expressionLong-term survival dataLow expressionHER2 antibodyX-tile programDisease-specific survivalLow HER2 expressionKaplan-Meier methodBreast cancer patientsExpression of HER2Higher antibody concentrationsLow antibody concentrationsConcentration of antibodyCancer patientsPatient outcomesSitu protein expression